Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study.
(2025 Sep)
PLoS Med 22(9): e1004732
Mugwanya KK, Saina M, Mugo NR, MaWhinney S, Morrow M, Schaafsma TT, Donnell D, Glidden DV, Ngure K, Brown CE, Rechkina EA, Chohan BH, Wu L, Hill E, Koome E, Akelo N, Mbaire S, Morrison SA, Kibatha M, Njeru I, Muriithi M, Coppinger C, Bushman L, Baeten JM, Anderson PL, Women Benchmark Study Team

Evaluating the effectiveness of a One-Stop PrEP Care model to enhance HIV prevention: a protocol for a cluster-randomised trial in Kisumu County, Kenya.
(2025 Sep 8)
BMJ Open 15(9): e097792
Kwach B, Odoyo JB, Lauff AR, Omollo V, Rono B, Ogello V, Mann V, Kwena Z, Thomas K, Sharma M, Morton JF, Ngure K, Bukusi E, Mugwanya KK, PrEP Care Team OS

Willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among black cisgender women in the Southern United States.
(2025)
PLoS One 20(9): e0330698
Shangani S, Reeves JM, Heron K, Sales JM, Mugwanya KK

"When he is around, I'll take the PrEP, but when he is not, I will not take PrEP": key influences on PrEP use decisions among women attending family planning clinics in Kenya.
(2025)
Front Med (Lausanne) 12(): 1552132
Ogello V, Beima-Sofie K, Urusaro S, Awuor M, Dollah A, Atieno W, Wandera C, Matemo D, Morton JF, Ngure K, Kinuthia J, Mugwanya KK

High acceptability, feasibility and sustainability of a direct-to-pharmacy differentiated PrEP delivery model in public health HIV clinics in Kenya: perspectives of PrEP clients and healthcare providers.
(2025 Jul)
J Int AIDS Soc 28 Suppl 3(Suppl 3): e26442
Owidi E, Ngure K, Ogello V, Wairimu N, Etyang' L, Waituika W, Mwangi M, Mwangi D, Maina S, Irungu E, Kiptinness C, Mugo N, Mugwanya K, Efficiency Study Team